← Leaderboards
Xiaojun Lian
Pennsylvania State University, The
$1,692,481
Attributed
$2,352,914
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $898.1K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,352,914 · 3
By mechanism
R01$1,320,866 · 1
R21$567,000 · 1
R56$465,048 · 1
Top collaborators
- Ying Mei2 shared
Most similar at Pennsylvania State University, The
Same institution · by research overlap
- Surojit Sarkar$5,561,420
- Na Xiong$9,136,479
- Connie J Rogers$513,181
Others in their field
Other Emerging Leaders on “Genes”
- Leonard Freedman · Leidos Biomedical Research, Inc.$97,908,773
- Yunda Huang · Fred Hutchinson Cancer Center$51,342,169
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$41,311,588
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Evan Z Macosko · Broad Institute, Inc.$32,734,698
Research focus
GenesInnovationT-LymphocyteTransplantationCellsImmuneIn VitroPropertyUnited StatesAffectIn VivoNatural Killer CellsHla AntigensAllogenicHomologous TransplantationGenerationsHeartHumanized MouseCardiacDesignClone CellsCardiac MyocytesCessation Of LifeCytolysis
Grant awards (7)
Nanowired hypoimmunogenic hPSC cardiac organoids for heart repair$647,308
R01 · FY2025 · HL
Nanowired hypoimmunogenic hPSC cardiac organoids for heart repair$673,558
R01 · FY2024 · HL
ModRNA-based Direct Programming of Universal Donor hiPSCs into Immune Evasive Beta Cells$224,570
R56 · FY2024 · DK · contact PI
ModRNA-based Direct Programming of Universal Donor hiPSCs into Immune Evasive Beta Cells$240,478
R56 · FY2023 · DK · contact PI
Stem cell immunoengineering for universal cardiac therapy via CRISPR-Cas9$214,663
R21 · FY2020 · EB · contact PI
Stem cell immunoengineering for universal cardiac therapy via CRISPR-Cas9$175,791
R21 · FY2019 · EB · contact PI
Stem cell immunoengineering for universal cardiac therapy via CRISPR-Cas9$176,546
R21 · FY2018 · EB · contact PI